BioNTech SE Sponsored ADR $BNTX Shares Purchased by Royal Bank of Canada

Royal Bank of Canada grew its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 15.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,991 shares of the company’s stock after acquiring an additional 6,308 shares during the period. Royal Bank of Canada’s holdings in BioNTech were worth $4,177,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Larson Financial Group LLC boosted its holdings in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG acquired a new position in shares of BioNTech in the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd raised its position in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the last quarter. Finally, Vestcor Inc purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $153,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Down 0.7%

BNTX stock opened at $92.12 on Friday. The firm has a fifty day moving average price of $91.59 and a two-hundred day moving average price of $96.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The firm has a market cap of $23.30 billion, a price-to-earnings ratio of -11.77 and a beta of 1.27.

BioNTech declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BNTX. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Citigroup cut their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Finally, Berenberg Bank decreased their price target on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.81.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.